Recent News

• 12.11.2025 - MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
• 12.11.2025 - MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer
• 12.11.2025 - MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential
• 12.10.2025 - MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach
• 12.01.2025 - MAIA Biotechnology Announces Open Market Purchases by CEO and Directors
• 11.21.2025 - MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025

Recent Filings

• 12.10.2025 - EX-99.1 EX-99.1
• 12.10.2025 - 8-K Current report
• 12.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.04.2025 - 4/A Statement of changes in beneficial ownership of securities
• 12.04.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 12.04.2025 - 4/A Statement of changes in beneficial ownership of securities
• 12.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.28.2025 - 4 Statement of changes in beneficial ownership of securities